Service Corporation International (NYSE: SCI) — A Demographically-Destined Death-Care Monopoly, Marked Down on a Mortality Blip

Independent equity research. The analysis below carries no recommendation and no price target. The single exception is the labeled Author's Take block immediately below.

⚡ Author’s Take

This block is the author’s own independent opinion and general information, not investment advice. Everything from the Executive Summary onward is written to take no position.

Verdict: HOLD, leaning accumulate-on-weakness — a genuinely high-quality, recession-proof compounder at a fair-not-cheap price, marked down on a transient volume miss. Accumulation zone ≈ $66–$72 (≈11.5–12x EV/EBITDA, ≈15.5–17x forward normalized EPS); the current ~$72.62 is reasonable, and the high-$60s — where it briefly traded after the Q1 print — is a good entry. Not-a-short.

Service Corporation International is the closest thing the public markets offer to a toll bridge on death: the largest operator (~18% share) in a recession-proof, demographically-tailwinded, structurally fragmented industry, with three reinforcing moats — purchasing/operating scale, the irreplaceable real estate under its 500 cemeteries (you essentially cannot get a new cemetery zoned and built in a desirable metro today), and a $17 billion preneed backlog of pre-sold, trust-funded funeral and cemetery contracts that lock in years of future revenue with embedded trust-fund upside. It compounds the way the best capital-return machines do: ~28% of the share count retired in six years, a steadily rising dividend, and disciplined bolt-on consolidation of the family-owned tail — a 255% total shareholder return over the past decade. And right now it is out of favor, down ~17% from its April-2026 all-time high after a Q1 funeral-volume miss that management — credibly, with twenty years of CDC-corroborated precedent — attributes to a tough flu-season comparison and a weak-mortality quarter, not lost share. “Had volumes been flat, EPS would have grown ~17%.”

The framing is abandoned defensive-quality at a fair price — the polar opposite of the cyclical-peak compounders trading at the top of their own valuation ranges. The factor tape confirms it: SCI screens as a low-beta (~0.36), value-and-dividend, low-volatility name with negative momentum (relative strength −17% from its peak), whose factor-cousins are dividend-aristocrat ETFs (SCHD, SPYD, REGL) — a left-behind income-and-quality compounder, not a crowded momentum trade and not a falling knife. That said, I stop short of an outright “buy here” for two honest reasons: at ~12.6x EV/EBITDA SCI is mid-range on its own history, not cheap, and this is a mid-single-digit grower whose signature tailwind (the boomer death wave) has been “about to arrive” for a decade while cremation steadily erodes the per-case economics. Conviction: medium. The single fact that flips me decisively bullish: funeral case volumes inflect positively in the back half of 2026 (confirming the miss was mortality timing, not a structural demand break) while preneed cemetery production keeps compounding double digits. The single fact that flips me bearish: the cremation mix-shift accelerates and average revenue per service stops outrunning it, so that “normalized” EPS stops growing and the ~17x multiple de-rates toward the low-teens. Tag: “The last monopoly on death, on sale because fewer people died last winter.”

📈 Stock Price Action — Five-Year Event Map

SCI’s five-year chart is a study in three acts: a COVID earnings spike, a multi-year “payback” stall, and a 2024–26 breakout that just gave back ground on a single soft quarter. The stock ran from roughly $48 (June 2021) to an all-time high of $87.32 on April 24, 2026, before falling to $72.62 (≈17% off the high) after the Q1-2026 funeral-volume miss. The 52-week range — $68.45 (June 2026) to $87.32 (April 2026) — captures the entire round-trip of the recent disappointment. (Prices adjusted; AZI 5-year CSV.)

Cycle narrative. Act one (events 1–2) is the COVID distortion: the pandemic’s excess deaths pulled forward funeral demand, producing a record 2021 (net income $803M), after which 2022–2023 was a “payback” period of normalizing volumes, flat EPS, and a stalled, range-bound stock. Act two (events 3–5) is the recovery and re-rating — earnings stabilized, the multi-decade demographic-tailwind story regained the narrative, and the stock broke out to a fresh all-time high of $87 by April 2026. Act three (event 6) is the present setback: a Q1-2026 funeral-volume miss — which management ties to a strong prior-year flu season and broadly weak first-quarter mortality (CDC-corroborated), not share loss — knocked the stock ~17% lower and reset expectations toward the lower half of the guidance range. The through-line: SCI’s price swings on the lumpy, unpredictable timing of the death rate, layered on top of a slow, durable compounding base of preneed sales, buybacks, and consolidation. [Fact — AZI CSV; Q1-26 transcript 2026-04-30]

1. Executive Summary

Service Corporation International is North America’s largest provider of death-care products and services, operating 1,485 funeral service locations and 500 cemeteries (including 312 combination funeral/cemetery sites) across 44 U.S. states, eight Canadian provinces, the District of Columbia, and Puerto Rico, under the Dignity Memorial brand. With roughly 18% market share in a deeply fragmented industry otherwise dominated by single-location, family-owned operators, SCI is the scaled consolidator in a business with three unusual and attractive properties: demand is recession-proof (death is non-discretionary), it carries a multi-decade demographic tailwind (the aging baby-boomer cohort lifts the U.S. death rate into the 2030s–2040s), and it generates a $17.0 billion preneed backlog of pre-sold, trust-funded contracts that lock in future revenue. [Fact — 10-K sci-20251231]

The business model has two engines. Funeral (≈60% of revenue) sells services and merchandise both atneed (after a death) and preneed (in advance, with cash held in trust or funded by insurance and recognized at need). Cemetery (≈40%) sells interment property (recognized largely as current revenue) plus merchandise/services (deferred), and manages perpetual-care trusts. The economics are strong and stable: ~30% EBITDA margins, ~11% ROIC (above cost of capital), and operating cash flow that converts at ~1.7x net income. As with several aggressive repurchasers, GAAP ROE (81%) and book value are distorted by a buyback-depleted equity base and should be ignored in favor of ROIC. [Fact — ROIC.ai]

The current setup is a transient earnings air-pocket against a durable franchise. 2020–2021 COVID excess deaths pulled forward demand (2021 net income peaked at $803M), creating tough 2022–2024 comparisons during which EPS held roughly flat (~$3.53) — masked by a ~28% reduction in share count. Q1-2026 then delivered a 6.6% funeral case-volume decline on a strong prior-year flu comp and weak first-quarter mortality, knocking the stock ~17% off its April-2026 all-time high. Management reaffirmed 2026 normalized EPS guidance of $4.05–$4.35 (funeral volume −1% to −3%, cemetery preneed up mid-single-digits), noting that “had volumes been flat, EPS would have grown ~17%.” The stock now trades at ~17x forward normalized earnings and ~12.6x EV/EBITDA — mid-range on its own multi-year history (P/E in only the 35th percentile of its own range), with low-beta, value/dividend factor characteristics and negative price momentum. Capital allocation is textbook: ~28% of shares retired in six years, a growing dividend (~34% payout), disciplined bolt-on M&A, and a just-raised ($472M) buyback authorization, all at ~3.7x leverage that management deliberately maintains. This is a high-quality, defensive compounder at a fair — not cheap — price, out of favor on a mortality blip. [Fact — Q1-26 transcript; ROIC.ai; AZI; 8-K 2026-06-11]

2. Business Overview

What the company does. SCI provides funeral and cemetery products and services — the logistics, merchandise, ceremony, and final disposition surrounding death. It operates the largest such network in North America, anchored by the Dignity Memorial brand (the first transcontinental death-care brand) and a portfolio of premium regional cemetery “parks” (e.g., Rose Hills in California). Headquartered in Houston, Texas, with ~25,000 associates, SCI has been the industry’s consolidator since the 1960s, assembling a footprint no competitor approaches in scale. [Fact — 10-K sci-20251231; Q1-26 transcript]

The two segments:

1. Funeral (~60% of revenue). Funeral services, cremations, caskets, urns, and related merchandise, plus general-agency commissions on insurance-funded preneed. Sold two ways: atneed (at the time of death) and preneed (arranged and paid in advance, with proceeds placed in trust or funded via third-party insurance, and revenue recognized when the service is ultimately delivered). The comparable cremation rate is now 64.4% (up 50 bps), a structurally important and rising mix factor. [Fact — 10-K]
2. Cemetery (~40% of revenue). Interment rights (graves, lawn crypts, mausoleum spaces, cremation niches), cemetery merchandise (markers, vaults), and services. Critically, preneed cemetery property is recognized as current revenue when sold (unlike preneed funeral, which is deferred), so cemetery sales production flows more quickly to the income statement. Cemeteries also carry perpetual-care trusts whose income funds grounds maintenance. [Fact — 10-K]

The preneed model — the structural crown jewel. SCI sells a large volume of funeral and cemetery arrangements before they are needed. The result is a $17.0 billion backlog of unfulfilled contracts (up from $16.0B a year earlier), trust-funded and growing, that converts to revenue as customers pass away — providing years of forward revenue visibility unmatched in consumer services. In 2025, $799.4M of revenue was recognized out of this backlog ($496.4M preneed + $303.0M atneed). The backlog also carries embedded trust-fund returns (SCI targets ~7%/year on combined trusts), so maturing contracts deliver more revenue than their original face value — a built-in, inflation-linked tailwind to average revenue per service. [Fact — 10-K; Q1-26 transcript]

Revenue character. Total revenue has been remarkably stable (~$4.1–4.3B since 2021), reflecting the non-discretionary, low-cyclicality nature of demand. The chief swing variable is the death rate, which is lumpy quarter-to-quarter (flu seasons, pandemics) but demographically rising over the long run. Recurrence is structural rather than contractual: every market SCI serves has an ongoing, demographically-driven flow of deaths, and the preneed backlog converts that flow into visible revenue. [Fact — ROIC.ai; 10-K]

Verdict. A simple, durable, recession-proof model with two complementary engines, an enormous pre-sold backlog, and an irreplaceable physical footprint. Reported revenue is stable; the near-term swing is mortality timing, the long-term driver is demographics, and the structural headwind is the rising cremation mix.

3. Industry Dynamics

Structure. The North American death-care industry is large, stable, and extraordinarily fragmented. SCI, the largest operator, holds only ~18% of industry revenue; the remainder is overwhelmingly single-location, family-owned funeral homes and cemeteries, frequently third-, fourth-, or fifth-generation businesses. The number-two and number-three public operators (Carriage Services, Park Lawn/legacy) and casket maker Matthews International are a fraction of SCI’s size. This fragmentation is the central structural feature: it gives the scaled consolidator a decades-long acquisition runway of independents whose owners are aging out, lack succession, and cannot match SCI’s purchasing, preneed sales infrastructure, or trust-management capability. [Fact — 10-K; Q1-26 transcript]

Demand — recession-proof and demographically rising. Death-care demand is the textbook non-discretionary, non-cyclical end market: the death rate does not fall in recessions. More importantly, it is set to rise structurally: the U.S. death rate is climbing as the large baby-boomer cohort ages, a tailwind that builds through the 2030s and peaks around 2040. Management explicitly frames the company as “moving into a period of meaningful demographic tailwinds.” The caveat: this tailwind is gradual and lumpy — any single quarter swings on flu seasons and short-term mortality (as Q1-2026’s −6.6% volume showed), and the boomer wave has been a “coming attraction” for years. [Fact — Q1-26 transcript; CDC/demographic data]

The cremation mix-shift — the defining structural headwind. Cremation now accounts for 64.4% of SCI’s services and is rising ~50 bps/year. Cremation carries a lower average revenue per service than traditional burial (less merchandise, no casket/vault, often no cemetery property), so the secular shift toward cremation is a persistent drag on funeral unit economics. SCI’s counter-strategy is threefold: (1) grow average revenue per service through pricing and premium offerings (up 3.5% in Q1-26 despite a higher cremation rate); (2) sell cremation memorialization on the cemetery side (niches, gardens, benches) — a market SCI concedes it had under-served and is now addressing via a new initiative (10 pilot markets in Q1-26, ~80 more rolling out in July); and (3) lean on the higher-margin cemetery segment. Whether these fully offset the mix-shift over time is the core long-term debate. [Fact — 10-K; Q1-26 transcript]

Regulation and trust dynamics. Death-care is state-regulated, with preneed trusting and perpetual-care requirements that vary by jurisdiction; SCI must maintain minimum trust funding and could, in adverse markets, be required to replenish trusts (a risk to earnings/cash flow). Trust-fund investment returns (targeted ~7%/yr) flow through to revenue as contracts mature and are a real but market-sensitive earnings input — Q1-26 trusts were down 0.7% before an April rebound. Licensing and consumer-protection rules (the FTC “Funeral Rule”) govern pricing disclosure. [Fact — 10-K; Q1-26 transcript]

Capital-cycle read (Marathon lens). A favorable supply side for the consolidator: the fragmented independent tail faces succession pressure, rising compliance/cost burdens, and no scale, and is steadily selling to SCI at sensible multiples. New supply is structurally constrained — you cannot readily build new cemeteries (land, zoning, perpetual-care obligations), which protects the value of SCI’s existing cemetery real estate. The one cloud is the cremation shift, which lowers the revenue intensity of each death even as the number of deaths rises. [Interpretation — framework-grounded]

Verdict: a structurally attractive, defensive industry for the scaled consolidator — recession-proof demand, a multi-decade demographic tailwind, a long fragmented-roll-up runway, and supply-constrained cemetery real estate — partially offset by the persistent cremation mix-shift that erodes revenue per death. Net structurally favorable, with SCI the clear beneficiary.

4. Competitive Position

The moat, named: economies of scale + irreplaceable real estate + a pre-sold backlog (a genuine, multi-source advantage). SCI’s competitive advantage is unusually well-rounded for a consumer-services business:

1. Scale economies (Greenwald’s economies-of-scale). At ~18% share and ~$4.3B revenue, SCI spreads purchasing (caskets, vaults), shared services, IT, a professional preneed sales force, and national advertising (the Dignity Memorial brand) across a base no independent can match. A single-location funeral home cannot run seminars across 30 markets, field a community-based preneed sales organization, or manage billion-dollar trust portfolios. [Interpretation, framework-grounded; Q1-26 transcript]
2. Irreplaceable cemetery real estate. SCI owns ~90% of its real estate, including 500 cemeteries — many in desirable, supply-constrained metros where new cemetery development is effectively impossible (zoning, land cost, perpetual-care liabilities). This is a durable local-monopoly asset: once a metro’s premium cemetery is full or owned by SCI, a competitor cannot replicate it. [Interpretation; 10-K]
3. The $17B preneed backlog and switching costs. Preneed contracts are, in effect, multi-year customer lock-in: a family that has pre-arranged and pre-paid a funeral with SCI is locked to SCI at need. The backlog is both a revenue-visibility asset and a switching-cost moat, and it compounds as preneed sales production grows (cemetery preneed +10% in Q1-26). [Interpretation; 10-K; transcript]

Does the moat show up in the numbers? Yes — durably. ROIC has held in the ~11–15% range across the entire 2020–2025 span (above WACC throughout), EBITDA margins have been rock-stable at ~30%, and SCI has delivered a 255% total shareholder return over the past decade. A business without a moat would see returns mean-revert toward cost of capital as competition arrived; SCI’s instead persist, supported by share gains via consolidation and the structural advantages above. The one honest qualifier: ROIC has drifted down from the 15.5% COVID-2021 peak toward ~11%, reflecting both the post-COVID normalization and the cremation mix-shift’s pressure on funeral economics. [Fact — ROIC.ai; DEF 14A]

Where the moat is weaker. (a) Cremation structurally lowers the revenue intensity of the core funeral product and is partly a commoditizing force — a direct-cremation provider with low overhead can undercut on price (SCI competes here via its own SCI Direct channel). (b) Brand matters less than in many consumer categories — death-care is a low-frequency, emotionally-driven, often locally-loyal purchase; Dignity Memorial helps but does not command a large price premium. © No contractual recurrence beyond the preneed backlog — atneed demand is a flow, not a subscription. [Interpretation; 10-K]

Versus the competitive set. SCI’s scale dwarfs the public peers — Carriage Services (CSV, the distant #2 funeral/cemetery operator) and Matthews International (MATW, primarily caskets/memorialization). Its real competition is the fragmented independent tail, against which SCI is the structural winner (scale, preneed infrastructure, balance sheet). Management noted in Q1-26 that some private competitors and suppliers reported worse volume comps than SCI in the quarter — evidence the volume dip was an industry-wide mortality phenomenon, not SCI share loss. [Fact — Q1-26 transcript]

Verdict: a durable, multi-source moat (scale + irreplaceable real estate + pre-sold backlog) that demonstrably persists in the returns, partially eroded over time by the commoditizing cremation shift. SCI is the clear and defensible leader of its industry — the rare consumer-services business with both a real moat and a structural growth tailwind.

5. Growth History and Forward Opportunities

Historical growth. SCI’s revenue has been deliberately stable (~$4.1–4.3B since 2021), so the growth story is told in EPS and cash flow per share, not the top line. Diluted EPS went $2.88 (2020) → $4.72 (2021 COVID peak) → $3.53 → $3.53 → $3.53 (2022–2024 payback) → $3.80 (2025). The flat 2022–2024 stretch reflects the COVID pull-forward “payback,” during which underlying EPS was supported by a ~20% reduction in share count. Net income peaked in 2021 and normalized; the per-share line held up far better because of relentless buybacks. This is the key pattern: SCI converts a low-growth revenue base into mid-to-high-single-digit per-share growth via margin stability, share reduction, and consolidation. [Fact — ROIC.ai]

The growth algorithm has four levers:

1. Demographic volume. The multi-decade rise in deaths as boomers age — the long-term organic tailwind, gradual and lumpy. [Q1-26 transcript]
2. Average revenue per service / per contract. Pricing power and premiumization, plus the maturing-backlog uplift (older preneed contracts mature with higher cumulative trust earnings, and SCI’s decision to stop delivering preneed merchandise at the time of sale raises the value at maturity). Core average revenue per funeral grew 3.5% in Q1-26 despite a higher cremation rate. [Q1-26 transcript]
3. Preneed sales production — building the backlog. Cemetery preneed production grew 10% in Q1-26 (large sales + velocity); funeral preneed +6%. Driven by sales-force headcount growth, seminars (lead generation outside the funeral home), lead-to-sale conversion, and large-sale ($100K+) cemetery property. [Q1-26 transcript]
4. Consolidation (M&A) + new builds. A $75–125M/year acquisition target rolling up independents, plus selective new-build funeral homes. [Q1-26 transcript]

Forward opportunities. (a) The demographic tailwind is the multi-year kicker — if/when death-rate growth reasserts after the COVID-payback distortion, SCI’s high-incremental-margin model (management cites ~80% funeral / ~75% cemetery incremental margins) converts volume to outsized EPS. (b) Cremation memorialization — the new cemetery-cremation initiative (10 → ~90 markets) directly attacks the mix-shift headwind and could add high-margin revenue. © Preneed compounding — double-digit cemetery preneed production builds tomorrow’s recognized revenue and backlog. (d) Continued buyback/consolidation. [Q1-26 transcript]

Verdict: medium-quality but durable growth. Organic revenue growth is low-single-digit and partly offset by cremation; the per-share compounding (mid-to-high single digit over time) is manufactured by stable margins, buybacks, preneed backlog conversion, and consolidation — and underwritten by a genuine, if gradual, demographic tailwind. This is a steady compounder, not a fast grower; the quality lies in the durability and predictability, not the rate.

6. Financial Quality

Margins and stability. SCI’s financial signature is stability: gross margin ~26%, EBITDA margin ~30% (30.5% in 2025, within a ~29–35% band since 2020), operating margin ~22–23%. These have held remarkably constant through COVID spikes, payback troughs, and cost inflation — evidence of pricing power and disciplined cost control (Q1-26: fixed-cost growth held to ~1%, well below inflation, in a down-volume quarter). [Fact — ROIC.ai; Q1-26 transcript]

Returns on capital — and the ROE/book-value trap. ROIC.ai reports an 81% ROE and a 6.4x price-to-book; both are artifacts to discard. SCI’s GAAP common equity (book value ~$11/share) is heavily depleted by years of buybacks (and the company carries negative tangible book — note the negative price-to-tangible-book in the data — owing to goodwill from decades of acquisitions). The meaningful return metric is ROIC, ~11% in 2025 (down from a 15.5% COVID-2021 peak; ~11% steady since), comfortably above SCI’s cost of capital but not spectacular, and gently pressured by the cremation mix. Use ROIC and EV-based multiples; never ROE or P/B for SCI. [Fact — ROIC.ai; QoE flag]

Cash flow quality — excellent. Operating cash flow was $943M in 2025 (adjusted ~$966M) against net income of $543M — a cash-flow-to-net-income ratio of ~1.7x, consistent for years, reflecting heavy non-cash depreciation/amortization and the favorable working-capital dynamics of preneed (cash collected in advance of revenue recognition). Capex is modest and partly growth-oriented (new cemetery development, new funeral-home builds): 2025 deployed ~$108M/quarter-run-rate of capital, of which a large share is maintenance plus cemetery development. SCI guides 2026 adjusted operating cash flow of $1.0–1.06B — a ~14% FCF/EV yield proxy at the current EV. The 2026 cash-tax rate is unusually low (~15–16%, aided by a renewable-energy investment) before normalizing to ~24–25% — a one-year cash tailwind to flag. [Fact — ROIC.ai; Q1-26 transcript]

Balance sheet. Net debt is ~$4.9B (total debt ~$5.2B less ~$0.26B cash), or 3.68x net debt/EBITDA — at the low end of management’s deliberate 3.5–4.0x target range. SCI runs leverage by design: its cash flows are stable and predictable (utility-like), so it optimizes the capital structure and returns the rest. Liquidity is robust (~$1.7B, including ~$1.45B undrawn revolver). A nuance worth understanding: SCI also carries large preneed trust assets and deferred-revenue/backlog liabilities on the balance sheet that net out — the relevant leverage is the ~3.7x corporate figure, which is moderate for this cash-flow profile. [Fact — Q1-26 transcript; ROIC.ai]

Quality-of-earnings summary:

• Clean: OCF/NI ~1.7x; ~30% margins stable through cycles; preneed provides negative-working-capital float. [positive]
• Distorted screens to discard: ROE (81%) and P/B — buyback-depleted/negative tangible equity. [QoE flag]
• Normalization nuances: GAAP EPS $3.80 vs normalized $3.81 vs adjusted $3.85 (2025) — small, legitimate gaps (tax-rate normalization, non-recurring items). 2026’s ~15–16% cash-tax rate is a one-year benefit. [QoE — DEF 14A; transcript]
• Market-sensitive input: trust-fund returns (targeted ~7%) flow to revenue at contract maturity; near-term volatility (Q1-26 trusts −0.7%) is muted by mark-to-market-over-time mechanics but is a real earnings variable. [watch]

Verdict: high-quality, highly stable, cash-generative economics that hold up across cycles, with strong cash conversion and a deliberately-levered but well-covered balance sheet. The headline ROE/P/B are misleading and must be replaced by ROIC (~11%, solid, gently declining). Economics are durable rather than improving — the cremation shift caps margin/return expansion, but the stability is the point.

7. Capital Allocation

SCI is a model capital allocator, and this — alongside the moat — is the core of the long-term case. The decade’s 255% total shareholder return, well ahead of its peer group and the S&P MidCap 400, is the scorecard. [Fact — DEF 14A 2026-03-26]

The priority framework (management’s stated “highest and best use”): (1) reinvest in the business (maintenance + cemetery development + new builds); (2) acquisitions (consolidate the fragmented tail, $75–125M/year target); (3) return the rest to shareholders via buybacks and a growing dividend; all while holding leverage in the 3.5–4.0x range. [Fact — Q1-26 transcript]

Buybacks — the dominant lever. SCI has retired roughly 28% of its shares in six years: shares outstanding fell from ~181M (2019) to ~130M (Q1-2026). Annual repurchases have been large and consistent ($517M/2020, $554M/2021, $661M/2022, $545M/2023, $254M/2024, $461M/2025; $143M in Q1-26 at ~$80/share). In June 2026 the board increased the buyback authorization by ~$472M — a signal of continued commitment and, implicitly, that management views the post-Q1 price as attractive. The buyback is the primary reason per-share metrics compounded through the flat 2022–2024 net-income stretch. [Fact — ROIC.ai; 8-K 2026-06-11; transcript]

Dividend. A steadily growing, well-covered supplement: DPS rose from ~$0.78 (2020) to ~$1.30 (2025), a ~34% payout ratio, ~1.9% yield. Conservative payout deliberately leaves room for the buyback and M&A. [Fact — ROIC.ai]

M&A — disciplined, accretive consolidation. SCI’s acquisitions are bolt-on roll-ups of independent funeral homes and cemeteries (2025: ~$101M deployed; Q1-26: ~$25M across Texas, Massachusetts, Alabama, North Carolina), executed as multi-generational, relationship-driven deals at sensible prices. This is the lowest-risk form of M&A — small, frequent, in the core competency, at the dominant consolidator’s cost of capital. Management is explicit that short-term volume softness will not derail the long-term, relationship-based M&A program. [Fact — Q1-26 transcript]

Incentive alignment. Long-term incentive compensation is tied to relative TSR versus the S&P MidCap 400 (target at the 50th percentile), governed by a normalized return-on-equity benchmark floor — a reasonable, market-aligned structure that paid out in 2025 on TSR outperformance. The annual plan and LTI use a mix of stock options, restricted stock, and performance units. The structure rewards relative outperformance and embeds a return-on-capital floor; it is not a pure ROIC governor, but it is meaningfully better than the metric-free or growth-only plans common in capital-intensive sectors. [Fact — DEF 14A 2026-03-26]

Governance demerits (mild). (a) Combined Chairman/CEO — Tom Ryan has been CEO since 2005 and Chairman since 2016 (21 years at the helm); a long, successful tenure, but concentrated. There is a Lead Independent Director (Marcus Watts). (b) No notable open-market insider buying (recent insider activity is routine director stock grants, not conviction purchases). Neither is disqualifying against a 255% decade TSR. [Fact — DEF 14A; AZI/Form 4]

Verdict: management has allocated capital exceptionally well — a disciplined, repeatable framework of reinvestment, accretive consolidation, large buybacks, and a growing dividend, executed at moderate leverage by a long-tenured, demonstrably value-creating team. This is the strongest pillar of the thesis alongside the moat, and the just-raised buyback authorization signals confidence at the current price.

8. Changes and Headwinds — Last Two Years

The COVID normalization (the dominant recent dynamic). The single most important context for SCI’s recent numbers is the pandemic distortion: 2020–2021 excess deaths pulled forward a large block of funeral demand (2021 net income peaked at $803M, EPS $4.72), followed by a multi-year “payback” of softer comparisons. This is why 2022–2024 EPS was roughly flat (~$3.53) and the stock stalled in the mid-$60s — not a business deterioration, but a return to trend after an unsustainable spike. Understanding this is essential to reading the franchise correctly. [Fact — ROIC.ai; Q1-26 transcript]

The Q1-2026 volume miss. Funeral case volume fell 6.6% in Q1-26 against a strong prior-year flu season and broadly weak first-quarter mortality (CDC-corroborated). Management cited 20 years of precedent (five prior instances of 4–9% Q1 declines, each followed by full-year improvement averaging +400 bps) and cross-checks (SCI Direct and preneed-to-atneed channels both down, private competitors faring worse) as evidence the dip is mortality timing, not share loss. Guidance was reaffirmed but skewed toward the lower half of the range. The market’s ~17% drawdown is the proximate “headwind.” [Fact — Q1-26 transcript]

The cremation mix-shift (the structural change). Cremation continues its steady rise (64.4%, +50 bps), pressuring funeral revenue per service. The strategic response — the cremation-cemetery memorialization initiative (10 pilot markets in Q1-26, ~80 more in July) — is a genuine, early-stage offset that management is “very excited” about but cautious not to over-claim (“10 markets does not make an initiative”). [Fact — Q1-26 transcript]

Preneed insurance-partner transition (now largely complete). SCI transitioned its core preneed insurance partner and moved SCI Direct from a trust to an insurance product — an 18-month distraction that pressured preneed sales, now “behind us,” with preneed production re-accelerating (cemetery +10%, funeral +6% in Q1-26). [Fact — Q1-26 transcript]

Capital-return continuity. Dividend increases, continued large buybacks, and the June-2026 $472M buyback-authorization increase — capital-return cadence intact and arguably stepped up into the price weakness. [Fact — 8-K 2026-06-11]

Verdict: net neutral, with a clear opportunity tint. The recent headwinds — the COVID payback and the Q1 volume miss — are transient and largely mechanical (mortality timing), not signs of franchise erosion; the preneed transition is resolving favorably; and management is leaning into the weakness with buybacks. The one genuinely structural “change” is the cremation mix-shift, which is gradual and being actively addressed. The demographic tailwind sits ahead as the multi-year positive.

9. Risk Analysis (Risk Matrix)

Catastrophic-loss / total-loss risk: very low. SCI is profitable, highly cash-generative, defensively positioned, and asset-backed (irreplaceable real estate + trust assets). The realistic downside is a de-rating plus prolonged volume/cremation pressure drawdown, not impairment or solvency. The leverage is moderate and well-covered; there is no plausible path to a total loss.

10. Valuation Discussion (Embedded Expectations)

Where the multiple sits. At ~$72.62, SCI trades at roughly 17x forward normalized 2026 EPS (~$4.20 midpoint of the $4.05–4.35 guide), ~19x trailing GAAP EPS ($3.80), and ~12.6x EV/EBITDA (EV ~$16.5B on ~$1.31B EBITDA; net debt ~$4.9B). AZI’s own-history percentiles: P/E in only the 35th percentile, composite 53rd — i.e., mid-range-to-cheap on its own multi-year history, not stretched. The honest cross-check is EV/EBITDA, which has been strikingly stable for SCI: 11.2x (2020), 10.9x (2021), 12.6x (2022), 12.0x (2023), 12.7x (2024), 12.2x (2025) — so the current ~12.6x is squarely mid-range, neither cheap nor expensive on the metric that matters most. [Fact — ROIC.ai; AZI]

The takeaway: fairly valued, not a bargain, not stretched. SCI is cheaper on P/E than its recent past (the de-rate from the April-2026 high, plus a lower current EPS base) but mid-range on EV/EBITDA. This is a high-quality defensive compounder at a reasonable price — the opposite of the cyclical-peak names trading at the top of their own ranges.

Embedded-expectations / reverse read. At ~12.6x EV/EBITDA and ~17x forward normalized earnings, the market is underwriting roughly:

1. Mid-single-digit per-share compounding — stable ~30% margins, low-single-digit revenue growth (demographics + pricing + preneed, net of cremation), and continued ~3–5%/year share reduction; and
2. The demographic tailwind eventually showing up in volume, without the cremation shift fully offsetting it; and
3. No multiple re-rating either way — the stable-~12x EV/EBITDA history holding.

That is a reasonable, not demanding set of expectations — which is why the risk/reward is more balanced (and more favorable on weakness) than for a richly-valued peak-cyclical. The upside optionality is the demographic tailwind inflecting (high incremental margins convert a volume recovery into outsized EPS, as the “flat-volume = +17% EPS” Q1 math shows); the downside is the cremation shift outrunning pricing while the multiple drifts toward the low-teens.

Scenario sketch (illustrative, not a price target):

• Bear: cremation pressure + soft mortality keep normalized EPS flattish and the multiple de-rates toward ~11x EV/EBITDA → modest downside, cushioned by the ~14% FCF yield and buyback.
• Base: mid-single-digit EPS compounding (margins + buyback + preneed + modest volume), multiple holds ~12x → high-single-digit total return (earnings growth + ~1.9% dividend + buyback).
• Bull: demographic volume inflects, incremental margins drive low-double-digit EPS growth, multiple holds or re-rates modestly → low-teens-plus TSR, as the past decade delivered.

Verdict. SCI is fairly valued on EV/EBITDA and modestly cheap on its own P/E history — a quality defensive compounder priced for reasonable, achievable expectations, with the demographic tailwind as a free-ish call option and the cremation shift as the offsetting structural risk. The valuation offers a workable margin of safety on weakness (high-$60s) that the peak-cyclical names lack. (No price target; no recommendation — see the Author’s Take for the subjective view.)

11. Variant Perception

Consensus view. SCI is broadly understood as a high-quality, defensive, recession-proof compounder with a demographic tailwind and excellent capital allocation — but one whose near-term earnings just disappointed on volume, leaving the Street cautious on the back-half recovery and the cremation trajectory. The factor tape frames it as a low-beta (~0.36) value/dividend/quality name with negative momentum (relative strength −17% from peak), whose factor-cousins are dividend-aristocrat ETFs — a left-behind income-and-quality compounder, neither a crowded momentum trade nor a falling knife. [Fact — FactorsToday; AZI]

The strongest bull case. SCI owns an irreplaceable, recession-proof, demographically-advantaged franchise — the only ~18%-share consolidator in a fragmented industry, with a $17B pre-sold backlog, supply-constrained cemetery real estate, and a 255% decade TSR from textbook capital allocation. It’s trading at a mid-range multiple after a transient, mortality-driven volume miss that 20 years of precedent says recovers. The demographic death-wave is a multi-year, high-incremental-margin tailwind (“flat volume = +17% EPS”), and management is buying back stock aggressively into the weakness. You’re paying a fair price for a durable compounder at a moment of maximum near-term pessimism.

The strongest bear case. This is a low-growth business (flat revenue, mid-single-digit per-share growth manufactured by buybacks) facing a permanent structural headwind — cremation — that steadily lowers the revenue intensity of every death, while the celebrated “demographic tailwind” has been perpetually one-or-two years away and is being offset by that very mix-shift and by younger cohorts’ preference for cheaper, less-elaborate dispositions. At ~12.6x EV/EBITDA (mid-range, not cheap) with ~3.7x leverage and a combined Chairman-CEO 21 years in the seat, there’s limited margin of safety if normalized EPS stops growing, and the multiple could drift to the low-teens.

The 3–5 assumptions that matter most:

1. Does funeral case volume inflect positively in 2H-2026 and beyond (mortality timing vs. structural demand break)?
2. Can average revenue per service keep outrunning the cremation mix-shift durably?
3. Does the boomer demographic tailwind actually show up in volume over the next 3–5 years?
4. Does the ~12x EV/EBITDA multiple hold, or de-rate toward the low-teens?
5. Does preneed production keep compounding (building tomorrow’s recognized revenue and backlog)?

Falsification tests. Bull is falsified if: funeral volumes stay structurally negative through a normal mortality environment (not just a tough flu comp) and average revenue per service fails to offset cremation — i.e., normalized EPS flatlines despite buybacks. Bear is falsified if: volumes recover in 2H-2026 as the 20-year pattern predicts and preneed/average-revenue growth sustains mid-single-digit+ normalized EPS compounding — confirming the franchise’s durability and the multiple.

Factor-positioning read (where consensus may be offsides). SCI is being sold as a disappointing-near-term name and held mainly by value/dividend/low-vol investors — the momentum crowd has left (relative strength −17% from peak). That is precisely the abandoned-quality setup where a high-quality, defensively-positioned compounder can be accumulated at a fair price while expectations are reset to the lower half of guidance. The risk to the contrarian read is that the cremation shift makes the “quality compounder” a slower compounder than the multiple implies — a fundamental de-rating, not just sentiment. The factor profile (low-vol, value, negative momentum) says the downside is more likely a slow grind than a crash, and the upside catalyst (volume inflection) is identifiable and near-term. [Interpretation — FactorsToday; AZI]

12. Fact vs. Interpretation Table

13. Open Questions

1. Does funeral volume inflect in 2H-2026, confirming the Q1 miss was mortality timing rather than a structural demand break? (The single biggest near-term swing.)
2. What is the durable trajectory of average revenue per service net of cremation — can pricing + memorialization + backlog-maturation uplift permanently outrun the mix-shift?
3. How fast and how large is the demographic tailwind, and how much is eaten by cremation and by younger cohorts’ lower ceremony spend?
4. What is the long-run “normal” ROIC — does it stabilize ~11%, or keep drifting down as cremation mixes up?
5. Succession — Tom Ryan has been CEO 21 years; what is the bench/plan behind the combined Chairman-CEO role?
6. Cremation-memorialization economics — what revenue/margin can the new cemetery-cremation initiative add at full (~90-market) rollout?
7. Trust-fund sensitivity — how much do sustained sub-7% market returns pressure recognized revenue and, in a severe drawdown, trigger replenishment?

14. What Must Be True

For the bull case to work:

• Funeral volumes must recover toward flat/positive as the COVID payback fades and the demographic tailwind builds — confirming the Q1-26 dip was mortality timing.
• Average revenue per service must durably outrun the cremation mix-shift (pricing + memorialization + backlog-maturation uplift).
• Preneed production must keep compounding (building recognized revenue and backlog), and capital allocation must continue (buybacks + accretive consolidation).
• The ~12x EV/EBITDA multiple must hold (or re-rate modestly).
• Falsification: normalized EPS flatlines across a normal mortality environment (volumes structurally negative, average revenue failing to offset cremation) → the “compounder” is stalling and the multiple de-rates.

For the bear case to work:

• Cremation accelerates and average revenue per service stops offsetting it, flattening normalized EPS.
• The demographic tailwind keeps disappointing/slipping while younger cohorts pressure ceremony spend.
• The multiple de-rates toward the low-teens P/E / low-11x EV/EBITDA as growth expectations reset.
• Falsification: volumes inflect positively in 2H-2026 (per the 20-year pattern) and preneed + pricing sustain mid-single-digit+ normalized EPS growth → the franchise compounds as advertised and the multiple is justified.

The honest synthesis: the near-term debate is mortality timing (volume recovery in 2H-2026), and the long-term debate is cremation vs. pricing/demographics. SCI is a genuinely high-quality, defensively-moated, well-allocated compounder; the question is not whether it’s a good business (it is) but whether mid-single-digit per-share growth at a mid-teens multiple is adequately compensated — and whether the demographic call option finally pays off before cremation erodes the per-death economics that fund it.

15. Source Appendix

See the separate Source Appendix (SCI_source_appendix.md) for the full citation list. Primary sources: SCI FY2025 Form 10-K (sci-20251231, filed 2026-02-12); FY2021–FY2024 10-Ks; Q1-2026 earnings call transcript (2026-04-30); DEF 14A proxy (2026-03-26); FY2025/Q1-26 earnings 8-Ks and the June-2026 buyback-authorization 8-K; ROIC.ai fundamentals and ratios; AZI valuation-percentile and news feeds; FactorsToday factor model; AZI 5-year price CSV; CDC mortality and U.S. demographic data; death-care industry/NACS-equivalent context.

APPENDIX A — Standard Diligence Questionnaire

Supplemental to the research memo. Grounded in the research log; Fact / Interpretation / Assumption labels applied where it matters.

General

What thoughtful questions have other investors asked about this company? From the Q1-26 call: (1) funeral volume trajectory through the quarter and into 2H (mortality timing vs structural); (2) preneed cemetery sustainability (large sales vs core velocity); (3) cremation mix-shift and the new cemetery-cremation memorialization initiative; (4) margin path by segment given down volumes; (5) trust-fund return volatility; (6) M&A pipeline and consolidation multiples; (7) EPS seasonality / the back-half ramp implied by guidance. [Fact — Q1-26 transcript]

Cyclicality & Earnings Nature

Are earnings at a cyclical high or low? Interpretation: near a normalized mid-point, recovering off a COVID-payback trough. Net income peaked in 2021 ($803M) on pandemic excess deaths, normalized through 2022–2024 (EPS ~$3.53), and is recovering ($3.80 in 2025; 2026 normalized guide $4.05–4.35). Q1-26 was a transient volume dip. Not a cyclical peak; arguably below the demographic trend line. [Fact/Interp — ROIC.ai; transcript]

Driven by external environment or internal actions? External: the death rate (lumpy short-term, rising long-term), trust-fund market returns, cremation mix. Internal: pricing, preneed sales production, cost control (fixed costs +1% in a down-volume quarter), buybacks, and consolidation. [Fact — transcript]

How stable are revenues? Very — ~$4.1–4.3B since 2021. Demand is non-discretionary; the swing variable is mortality timing. Gross/EBITDA margins ~26%/~30% are rock-stable. [Fact — ROIC.ai]

Outlook for products/services? Funeral: low-single-digit, pressured by cremation but supported by pricing/backlog maturation. Cemetery: stronger (preneed production +10% Q1-26), the growth engine. Long-run: demographic volume tailwind. [Fact/Interp — transcript]

How big is this market — growing or shrinking? North American death-care is large, stable, and set to grow in volume as boomers age (death rate rising into the 2030s–40s); revenue-per-death pressured by cremation. Domestic (US + Canada). Consolidation runway is multi-decade. [Fact/Interp — transcript; demographic data]

Business Quality & Competitive Moat

Is the industry getting more or less competitive? Stable-to-consolidating. The fragmented independent tail is selling to SCI; cremation introduces low-overhead direct-cremation price competition (SCI competes via SCI Direct). [Interpretation — transcript]

How profitable (ROIC, ROE)? ROIC ~11% (>WACC, down from 15.5% COVID peak). ROE 81% and P/B are distorted (buyback-depleted, negative tangible equity) — ignore them. [Fact — ROIC.ai; QoE flag]

How profitable is the industry; barriers to entry? Attractive for the scaled operator; high barriers in cemeteries specifically (you cannot readily build new ones — land/zoning/perpetual-care). Funeral barriers are lower (local independents), which is why consolidation, not greenfield, is the game. [Interpretation; 10-K]

Can the business be easily understood? Mostly — two segments, preneed/atneed. The complexity is preneed trust accounting and revenue deferral (preneed funeral deferred to need; preneed cemetery property recognized currently; trust returns mature with the backlog). [Fact — 10-K]

Undermined by foreign low-cost labor? No — local, physical, service-based; not offshorable. [Fact]

Do brands matter? Modestly. Dignity Memorial provides scale advertising and trust, but death-care is low-frequency, emotional, locally-loyal; no large brand price premium. [Interpretation]

Switching costs? Yes, via preneed — a pre-arranged, pre-paid contract locks the family to SCI at need. Atneed demand has no lock-in. [Fact/Interp — 10-K]

Financial Condition & Balance Sheet

Assets not fully recognized on the balance sheet? Yes — the irreplaceable cemetery real estate (owns ~90%, carried at depreciated/historical cost) and the embedded value of the $17B preneed backlog and trust portfolios. Economic value exceeds GAAP book (which is buyback-depleted/negative tangible). [Interpretation; 10-K]

Off-balance-sheet liabilities? Preneed/perpetual-care obligations are largely on balance sheet (deferred revenue, trust liabilities). State trust-replenishment requirements are a contingent risk in severe market drawdowns. [Fact — 10-K]

How conservative is the accounting? Reasonable but complex; OCF/NI ~1.7x corroborates earnings quality; normalized vs GAAP vs adjusted EPS gaps are small and disclosed. Trust mark-to-market is muted-over-time by the maturity mechanism. [Fact/QoE — transcript; DEF 14A]

How CapEx-hungry? Moderate — maintenance plus cemetery development and new builds (~$108M/quarter run-rate in Q1-26, much of it growth/development). Cash conversion is strong. [Fact — transcript]

Capital Allocation & Management

How much FCF, and how is it used? Adjusted operating cash flow ~$966M (2025); 2026 guide $1.0–1.06B. Priority: reinvest → acquisitions ($75–125M/yr) → buybacks + dividend; leverage held 3.5–4.0x. [Fact — transcript]

Significant acquisitions recently? Ongoing bolt-on consolidation (~$101M in 2025; ~$25M Q1-26 across TX/MA/AL/NC) — small, frequent, in-core, accretive. [Fact — transcript]

Buying back shares? Yes, aggressively — ~28% of shares retired since 2019 (181M→130M); $461M in 2025; +$472M authorization June 2026. [Fact — ROIC.ai; 8-K]

Issuing shares to insiders? Routine equity comp (options/RS/performance units); net effect strongly share-reductive. [Fact]

Compensation policy / motivations? LTI = relative TSR vs S&P MidCap 400 (50th-pctile target) with a normalized-ROE benchmark floor; reasonable alignment, paid out on TSR outperformance. CEO Tom Ryan since 2005 / Chair since 2016 (combined, Lead Independent Director present). 255% decade TSR. [Fact — DEF 14A]

Valuation & Market Data

ADR, MLP, or K-1 issuer? No — standard U.S. C-corp common stock; 1099 dividends; no K-1. [Fact]

Dividend policy? Growing, well-covered: ~$0.78 (2020) → ~$1.30 (2025), ~34% payout, ~1.9% yield; subordinate to buyback. [Fact — ROIC.ai]

How profitable? ~30% EBITDA margins, ~11% ROIC, ~1.7x OCF/NI — strong and stable. [Fact]

Net income diverging from CFO? CFO consistently exceeds NI (~1.7x) — preneed float + heavy D&A; favorable, no adverse divergence. [Fact — ROIC.ai]

Risks & Downside

What would cause the stock to decline? (1) Cremation eroding revenue per death faster than pricing offsets; (2) prolonged death-rate softness / demographic tailwind disappointing; (3) multiple de-rating from ~12.6x toward low-teens; (4) trust-fund drawdown; (5) rising rates on floating debt. [Interpretation — transcript; AZI]

Risk of catastrophic loss? Very low — profitable, cash-generative, asset-backed, defensively positioned, moderately levered. [Fact/Interp]

Chance of total loss? Negligible — no plausible path absent an extreme, sustained structural collapse in ceremony spend. [Interpretation]

Recent News & Events

Has the business environment changed recently? Two things: (1) the Q1-26 funeral-volume miss (−6.6%, mortality timing per CDC/peers) that dropped the stock ~17% from its April-2026 ATH; (2) the ongoing cremation mix-shift and SCI’s new cemetery-cremation memorialization initiative. The COVID-payback distortion is fading. [Fact — transcript; AZI CSV]

Significant acquisitions? Ongoing bolt-ons; no transformational deal. [Fact]

Accounting-policy changes? None material; an operational change to stop delivering preneed merchandise at time of sale raises backlog-maturation value. [Fact — transcript]

Other recent changes? $472M buyback-authorization increase (June 2026); dividend growth; preneed insurance-partner transition now complete; ~15–16% 2026 cash-tax rate (renewable-energy benefit, normalizing later). [Fact — 8-K; transcript]

APPENDIX B — Source Appendix

Primary sources first. All figures reconciled to filings where possible; third-party aggregated data (ROIC.ai, AZI, FactorsToday) labeled as such and used as cross-checks, not primary authority.

Primary — SEC filings (EDGAR, CIK 0000089089)

1. Form 10-K, FY2025 (sci-20251231, filed 2026-02-12) — network (1,485 funeral service locations + 500 cemeteries incl 312 combos; 44 states + 8 Canadian provinces + DC + PR; ~25,000 associates); ~18% NA market share; $17.0B preneed backlog (vs $16.0B 2024); $799.4M revenue recognized from backlog ($496.4M preneed + $303.0M atneed); comparable cremation rate 64.4% (+50bps); owns ~90% of real estate; Dignity Memorial brand; preneed/trust accounting; risk factors (trust replenishment, regulation). https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000089089
2. Forms 10-K, FY2021–FY2024 — multi-year revenue, EPS, backlog, cremation-rate, and segment history.
3. Q1-2026 earnings call transcript (2026-04-30, via ROIC.ai) — Chairman/CEO Tom Ryan, CFO Eric Tanzberger; adj EPS $0.97; funeral case volume −6.6% (flu comp / weak mortality, CDC-corroborated); “flat volume = +17% EPS”; cemetery revenue +7%, preneed cemetery production +10%; reaffirmed 2026 normalized EPS guide $4.05–4.35 (funeral volume −1% to −3%); adj OCF guide $1.0–1.06B; leverage 3.68x; $190M returned in Q1 ($143M buyback @ ~$80 + $47M div); shares ~130M; demographic-tailwind framing; cremation-memorialization initiative; trust returns; M&A pipeline ($75–125M/yr).
4. DEF 14A proxy (sci-20260326, filed 2026-03-26) — LTI = relative TSR vs S&P MidCap 400 (50th-pctile target) with normalized-ROE benchmark floor; options/RS/performance units; 255% decade TSR; CEO Ryan since 2005 / Chair since 2016; Lead Independent Director Marcus Watts; 2025 normalized EPS $3.81 vs adjusted $3.85; adj OCF $966M.
5. Form 8-K, 2026-06-11 — board increased share-repurchase authorization by ~$472M (Reg FD).
6. Forms 8-K, 2026-04-29 and Q1-26 — first-quarter results and conference-call materials.
7. Forms 4 / insider (May 2026) — routine director stock grants (2,448 shares each); no notable open-market purchases.

Third-party quantitative (cross-check, reconciled to filings)

8. ROIC.ai MCP — income statement, balance sheet, cash flow, profitability ratios (ROIC ~11% FY25; ROE 81% flagged distorted; EBITDA margin ~30%), per-share data, enterprise value (EV ~$16.5B; net debt ~$4.9B; EV/EBITDA ~12.6x TTM), valuation multiples (EV/EBITDA history ~11–13x, 2019–2025).
9. AZI fundamentals — valuation_index (2026-06-18) — P/E 16.4x (35th pctile own-history), P/B 6.4x (77.5th), P/S 2.38x (46.9th), composite 53rd; price $72.62.
10. AZI news feed (34 articles) — Q1-26 earnings miss / “down 5.9% since earnings”; board buyback-authorization increase ~$472M (2026-06-11); routine director grants.
11. AZI 5-year price CSV — 5yr range ~$47.75 (Jun-2021) → $87.32 ATH (2026-04-24) → $72.62; 52-wk $68.45–$87.32; year-end closes 2020–2025; beta 0.355.
12. FactorsToday — /stock-info (beta 0.355, alpha −0.02, rs_12m −5.15%, rs_peak −16.83%, m3/m6 negative); /stock-loadings (Value 0.40, DividendYield 0.28, Quality, negative Growth/Momentum/BetaFactor; R² ~0.27); /leaderboard (y5 +7.9% annualized, Sharpe 0.24); /related-stocks (dividend ETFs SCHD/SPYD/REGL/RDIV + ITW).

Industry / peer context

13. CDC mortality data / U.S. demographic projections — first-quarter mortality trends (referenced by management); long-run death-rate rise as boomers age into the 2030s–2040s.
14. Death-care industry structure — fragmentation (majority single-location family-owned); cremation-rate trend (NFDA/industry); FTC Funeral Rule; state preneed/perpetual-care trust regulation.
15. Public peers — Carriage Services (CSV, #2 funeral/cemetery), Matthews International (MATW, caskets/memorialization) — scale and competitive context (public record).

Frameworks

16. Greenwald & Kahn, Competition Demystified — economies-of-scale + customer-captivity + irreplaceable-asset moat analysis; ROIC/share-stability tests applied to SCI.
17. Chancellor (Marathon), Capital Returns — capital-cycle read of the consolidating, supply-constrained death-care industry.

Note: ROIC.ai, AZI, and FactorsToday are third-party aggregated/estimated data, used as cross-checks. Where they conflict with the 10-K, the filing governs. No analyst price target or rating is adopted as the author’s view.